Login / Signup
Pharmacological rationale for antihypertensive drug choice on COVID-19-affected patients: ACEI/ARB might not increase their susceptibility.
Hong-Jin Zhao
Xiao-Mei Yang
Ai-Hong Wang
Yan Li
Published in:
Journal of cellular and molecular medicine (2020)
Keyphrases
</>
end stage renal disease
coronavirus disease
sars cov
newly diagnosed
chronic kidney disease
blood pressure
peritoneal dialysis
emergency department
patient reported outcomes
patient reported
decision making
hypertensive patients